scanance.
Sign inGet Premium
TW

Twist Bioscience Corporation

TWSTHealthcareNASDAQ

Diagnostics & Research

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$376.6M
+20.3% YoY
Net Income
-$77.7M
+62.8% YoY
EBITDA
-$111.4M
+22.9% YoY
Free Cash Flow
-$58.5M

Scan Results

Daily timeframe
DateIndicatorDetails
Loading...
About Twist Bioscience Corporation

Part of the healthcare sector, Twist Bioscience Corporation (TWST) is listed under Diagnostics & Research. The company carries a $4.16B market cap, placing it firmly in the mid-cap category. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Key stats
Market Cap$4.16B
Fwd P/E-32.62
EPS$-1.32
Beta2.23
52W Change+115.2%
ROE-18.2%
Analysis

Twist Bioscience Corporation holds $171.7M in cash against $110.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$58.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -18.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $203.6M (2022) to $376.6M (2025), reflecting a 85% increase over the period.

Twist Bioscience Corporation's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Twist Bioscience Corporation's trajectory.

Links
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms